Advertisement
Screener

QUIDELORTHO CORP (QDEL) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

QUIDELORTHO CORP Operating Cash Flow

QUIDELORTHO CORP (QDEL) reported Operating Cash Flow of -$143.60 million for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07

  • QUIDELORTHO CORP net cash provided by (used in) operating activities for the quarter ending 2026-06-28 was -$110.60M.
  • QUIDELORTHO CORP net cash provided by (used in) operating activities for the quarter ending 2026-03-29 was -$33.00M, a 150.30% decline year-over-year.
  • QUIDELORTHO CORP net cash provided by (used in) operating activities for the quarter ending 2025-12-28 was $131.90M, a 107.06% increase year-over-year.
  • QUIDELORTHO CORP net cash provided by (used in) operating activities for the quarter ending 2025-09-28 was -$45.50M, a 138.59% decline year-over-year.
  • QUIDELORTHO CORP net cash provided by (used in) operating activities for fiscal 2025 was $105.20M, a 26.75% increase from fiscal 2024.
  • QUIDELORTHO CORP net cash provided by (used in) operating activities for fiscal 2024 was $83.00M, a 70.38% decline from fiscal 2023.
  • QUIDELORTHO CORP net cash provided by (used in) operating activities for fiscal 2023 was $280.20M, a 68.35% decline from fiscal 2023.
  • QUIDELORTHO CORP net cash provided by (used in) operating activities for fiscal 2023 was $885.30M, a 9.85% increase from fiscal 2022.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 12 month
2026-06-28-$110.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
-$143.60M
10-Q · filed 2026-08-07
-$11.70M
derived: sum of 3 quarters · filed 2026-08-07
-$57.20M
derived: sum of 4 quarters · filed 2026-08-07
2026-03-29-$33.00M
10-Q · filed 2026-05-06
$98.90M
derived: sum of 2 quarters · filed 2026-05-06
$53.40M
derived: sum of 3 quarters · filed 2026-05-06
$6.60M
derived: sum of 4 quarters · filed 2026-08-07
2025-12-28$131.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$86.40M
derived: sum of 2 quarters · filed 2026-02-19
$39.60M
derived: sum of 3 quarters · filed 2026-08-07
$105.20M
10-K · filed 2026-02-19
2025-09-28-$45.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$92.30M
derived: sum of 2 quarters · filed 2026-08-07
-$26.70M
10-Q · filed 2025-11-06
$37.00M
derived: sum of 4 quarters · filed 2026-08-07
2025-06-29-$46.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07
$18.80M
10-Q · filed 2026-08-07
$82.50M
derived: sum of 3 quarters · filed 2026-08-07
$200.40M
derived: sum of 4 quarters · filed 2026-08-07
2025-03-30$65.60M
10-Q · filed 2026-05-06
$129.30M
derived: sum of 2 quarters · filed 2026-05-06
$247.20M
derived: sum of 3 quarters · filed 2026-05-06
$149.30M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-29$63.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$181.60M
derived: sum of 2 quarters · filed 2026-02-19
$83.70M
derived: sum of 3 quarters · filed 2026-02-19
$83.00M
10-K · filed 2026-02-19
2024-09-29$117.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$20.00M
derived: sum of 2 quarters · filed 2025-11-06
$19.30M
10-Q · filed 2025-11-06
$99.70M
derived: sum of 4 quarters · filed 2026-02-19
2024-06-30-$97.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$98.60M
10-Q · filed 2025-08-06
-$18.20M
derived: sum of 3 quarters · filed 2026-02-19
$23.30M
derived: sum of 4 quarters · filed 2026-02-19
2024-03-31-$700.00K
10-Q · filed 2025-05-08
$79.70M
derived: sum of 2 quarters · filed 2026-02-19
$121.20M
derived: sum of 3 quarters · filed 2026-02-19
$90.60M
derived: sum of 4 quarters · filed 2026-02-19
2023-12-31$80.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19
$121.90M
derived: sum of 2 quarters · filed 2026-02-19
$91.30M
derived: sum of 3 quarters · filed 2026-02-19
$280.20M
10-K · filed 2026-02-19
2023-10-01$41.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
$10.90M
derived: sum of 2 quarters · filed 2024-11-08
$199.80M
10-Q · filed 2024-11-08
$369.20M
derived: sum of 4 quarters · filed 2025-02-27
2023-07-02-$30.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
$158.30M
10-Q · filed 2024-08-01
$327.70M
derived: sum of 3 quarters · filed 2025-02-27
$318.00M
derived: sum of 4 quarters · filed 2025-02-27
2023-04-02$188.90M
10-Q · filed 2024-05-09
$358.30M
derived: sum of 2 quarters · filed 2025-02-27
$348.60M
derived: sum of 3 quarters · filed 2025-02-27
$573.30M
derived: sum of 4 quarters · filed 2025-02-27
2023-01-01$169.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$159.70M
derived: sum of 2 quarters · filed 2025-02-27
$384.40M
derived: sum of 3 quarters · filed 2025-02-27
$885.30M
10-K · filed 2025-02-27
2022-10-02-$9.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$215.00M
derived: sum of 2 quarters · filed 2023-11-02
$715.90M
10-Q · filed 2023-11-02
$1.04B
derived: sum of 4 quarters · filed 2024-08-01
2022-07-03$224.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$725.60M
10-Q · filed 2023-08-09
$1.05B
derived: sum of 3 quarters · filed 2024-08-01
$1.12B
derived: sum of 4 quarters · filed 2024-08-01
2022-04-03$500.90M
10-Q · filed 2023-05-04
$822.30M
derived: sum of 2 quarters · filed 2024-08-01
$899.30M
derived: sum of 3 quarters · filed 2024-08-01
2022-01-02$321.40M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01
$398.40M
derived: sum of 2 quarters · filed 2024-08-01
$805.90M
10-K/A · filed 2024-08-01
2021-10-03$77.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04
$484.50M
10-Q · filed 2022-11-04
2021-07-04$407.50M
10-Q · filed 2022-08-05
2021-01-03$629.70M
10-K · filed 2023-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92